as part of eisai’s global manufacturing system, eisai suzhou factory carries out all manufacturing processes from local production of tablets, capsules and injections to the repackaging of the imported semi-products. the factory sits on a sprawling land of 25,000m2 in suzhou industrial park and is equipped with state-of-the-art machineries. in 2004, the total investment of eisai increased to $110 million, while its registered capital increased to $38.54 million. in order to improve its production capacity, eisai began the construction of the second building of production in 2005 thereby enabling the suzhou factory to meet increasing demands for high quality eisai medicines not only in china but elsewhere in the world where it supplies those medicines. to sustain expanding operations in china, in 2010, eisai increased the total investment to $230 million and the registered capital to $78.54 million, and purchased about 134,000m2 of land in suzhou industrial park for construction of a new facility that will combine r&d, production and logistics. the eisai injection plant in suzhou industrial park was completed on november 18th 2014. currently, it has obtained the gmp certificate to conduct the repackaging work of imported small volume injections. the eisai suzhou injection plant, which covers an area of 3,500m2 and a structure area of 6,200m2, will be used as the main production base of mecobalamin injection at the beginning, with an annual production capacity of 60 million vials. in the future, this new facility will become one of eisai’s knowledge centers in the world.
- locally manufactured products
mecobalamin tablets, betahistine mesylate tablets, donepezil hydrochloride tablets, eperisone hydrochloride tablets, coenzyme q10 tablets, teprenone capsules, and sodium rabeprazole enteric coating tablets
- repackaged imported products
mecobalamin injection, compound glycyrrhizin, compound glycyrrhizin injection, mitiglinide calcium tablets, and menatetrenone soft capsules